EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 173 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling... January 19, 2026 Cancer Research UK spin-out goes public, ready to invest more in... May 17, 2021 EMA Recommends Extension of Indications for Lorlatinib December 20, 2021 Does Sugar Cause Cancer? November 9, 2021 Load more HOT NEWS Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... EMA Recommends Extension of Indications for Inotuzumab Ozogamicin TP53 Allelic State is Critical in Myelodysplastic Syndromes Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer...
